Levocetirizine Dihydrochloride
FDA-approved product (tablet, oral), marketed as Levocetirizine Dihydrochloride, Levocetirizine Hydrochloride, Xyzal and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic disease
- Rhinitis, Allergic, Perennial
- Seasonal allergic rhinitis
- Skin disease
- Urticaria
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Piperazine derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Levocetirizine Dihydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
NCT00524836 · start 2003-09
Registered record
- Registry ID
- NCT00524836
- Conditions
- Rhinitis; Allergic; Perennial
- Interventions
- levocetirizine dihydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-09
- Completion
- 2004-02
- Enrolment
- 71
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRhinitis; Allergic; PerennialInterventionlevocetirizine dihydrochloridePhasePhase 3Registry statusCompletedTo Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
NCT00525278 · start 2003-08
Registered record
- Registry ID
- NCT00525278
- Conditions
- Rhinitis; Allergic; Seasonal
- Interventions
- Levocetirizine dihydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2003-10
- Enrolment
- 67
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRhinitis; Allergic; SeasonalInterventionLevocetirizine dihydrochloridePhasePhase 3Registry statusCompletedStudy to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria
NCT00525382 · start 2003-08
Registered record
- Registry ID
- NCT00525382
- Conditions
- Urticaria
- Interventions
- levocetirizine dihydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2004-03
- Enrolment
- 134
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrticariaInterventionlevocetirizine dihydrochloridePhasePhase 3Registry statusCompletedEfficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis
NCT00542607 · start 2002-09
Registered record
- Registry ID
- NCT00542607
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- levocetirizine dihydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-09
- Completion
- 2002-12
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRhinitis, Allergic, SeasonalInterventionlevocetirizine dihydrochloridePhasePhase 4Registry statusCompletedPrevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
NCT00152464 · start 2002-03-20
Registered record
- Registry ID
- NCT00152464
- Conditions
- Dermatitis, Atopic
- Interventions
- Placebo; Levocetirizine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-03-20
- Completion
- 2006-03-15
- Enrolment
- 514
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis, AtopicInterventionPlacebo; LevocetirizinePhasePhase 3Registry statusCompleted